207
Participants
Start Date
December 31, 2016
Primary Completion Date
September 30, 2018
Study Completion Date
October 31, 2018
Pimavanserin
Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
Placebo
Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
Manhattan Behavioral Medicine, New York
Finger Lakes Clinical Research, Rochester
UPenn, Philadelphia
Carolina Clinical Trials, Inc., Charleston
iResearch Atlanta, Decatur
Emory University School of Medicine, Atlanta
CNS Health care (Jacksonville), Jacksonville
Meridien Research, Maitland
CNS Health care (Orlando), Orlando
Meridien Research, Bradenton
UAB, Birmingham
Neuro-Behavioral Clinical Research, Canton
IPC Research, Waukesha
Alexian Brothers Center for Psychiatric Research, Hoffman Estates
Alam Medical Research, INC, Chicago
St. Louis Clinical Trials, St Louis
KUMC, Wichita
Woodland Research Northwest, Rogers
IPS Research, Oklahoma City
Rivus Wellness & Research Institute, Oklahoma City
Pillar Clinical Research, Richardson
FutureSearch Trials of Dallas, L.P., Dallas
UTSW, Dallas
Baylor College of Medicine, Houston
Ericksen Research & Development, Clinton
Altea Research, Las Vegas
Collaborative Neuroscience Network, LLC, Torrance
Schuster Medical Research Institute, Sherman Oaks
Pacific Clinical Research Medical Group, Upland
Synergy San Diego, National City
Viking Clinical Research, Temecula
Collaborative Neuroscience Network, LLC, Garden Grove
Pacific Research Partners, LLC, Oakland
Summit Research Network (Oregon), Portland
Hassman Research Institute, Berlin
BTC of Lincoln, Lincoln
Lead Sponsor
ACADIA Pharmaceuticals Inc.
INDUSTRY